CD34+ hematopoietic stem cells

CD34+ hematopoietic stem cells (HSCs) are multipotent progenitor cells characterized by the expression of the CD34 surface glycoprotein, a transmembrane phosphoglycoprotein involved in cell-cell adhesion. In clinical cell therapy, these cells are typically isolated from bone marrow or mobilized peripheral blood (using agents like G-CSF) and purified using immunomagnetic selection systems such as the CliniMACS CD34 Reagent System. This therapeutic approach has been pioneered by institutions including **Perugia University**, which developed 'megadose' T-cell depleted CD34+ transplants to overcome HLA barriers in haploidentical hematopoietic stem cell transplantation for high-risk **Acute Myeloid Leukemia (AML)** and other hematologic malignancies. By depleting T-cells while providing a high dose of stem cells, the protocol facilitates engraftment and reduces the risk of Graft-versus-Host Disease (GvHD). Additionally, **Columbia University** has investigated the infusion of donor-derived CD34+ cells in **Intestinal Transplantation** to induce mixed chimerism, aiming to promote donor-specific tolerance and minimize long-term immunosuppression. Beyond hematologic reconstitution, these cells are studied for their pro-angiogenic properties in treating **Ischemic Heart Disease** and **Peripheral Artery Disease**.

Other names

CD34+ stem cellsMegadose CD34+ cellsPurified hematopoietic stem cellsCD34-selected hematopoietic stem cellsCD-34-selected hematopoietic stem cellsCD 34-selected hematopoietic stem cells